• Citer

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

par Almhanna, Khaldoun;Bendell, Johanna;Bols, Alain;Feliu, Jaime;Starling, Naureen;Enzinger, Peter;Mahalingham, Devalingham;Messersmith, Wells;Yang, Huyuan;Fasanmade, Adedigbo A.A.;Danaee, Hadi;Wright, David;Kalebic, Thea;Mercade, Teresa Macarulla;Van Laethem, Jean-Luc ;Gracian, Antonio Cubillo;Guillen-Ponce, Carmen;Faris, Jason;López, Carolina Muriel;Hubner, Richard R.A.
Référence Investigational new drugs, 35, 5, page (634-641)
Publication Publié, 2017-10

Article révisé par les pairs

• Détails
• Contenu

Titre:	A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C
Auteur:	Almhanna, Khaldoun; Bendell, Johanna; Bols, Alain; Feliu, Jaime; Starling, Naureen; Enzinger, Peter; Mahalingham, Devalingham; Messersmith, Wells; Yang, Huyuan; Fasanmade, Adedigbo A.A.; Danaee, Hadi; Wright, David; Kalebic, Thea; Mercade, Teresa Macarulla; Van Laethem, Jean-Luc; Gracian, Antonio Cubillo; Guillen-Ponce, Carmen; Faris, Jason; López, Carolina Muriel; Hubner, Richard R.A.
Informations sur la publication:	Investigational new drugs, 35, 5, page (634-641)
Statut de publication:	Publié, 2017-10
Sujet CREF:	Cancérologie
	Pharmacologie
Mots-clés:	Antibodies/immunoconjugates
	Antibody immunotherapy
	Antibody–drug conjugate
	Guanylyl cyclase C
	Phase II trials_Pancreatic cancers: Pancreas
	TAK-264
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-6997
	info:doi/10.1007/s10637-017-0473-9
	info:scp/85019651779